LumiraDx Investor Presentation Deck

Our Pipeline Will Support Sustainable Growth Planned Submissions Disease Area and Test Respiratory Coagulation Cardiovascular Diabetes Global Health Inflammation COVID Ultra CRP Flu A/B Ultra RSV Ultra Strep A INR D-Dimer NT-ProBNP HS Troponin BNP Na/K Lipids HbAle TB HIV Viral Load CRP ProcalcHonin Concept Qual Immunoassay Feasibility Development Quant Immunoassay Verification & Validation Molecular Regulatory E Enzyme IVDR/ CE Mark Complete Complete Complete Complete Complete HI 2023 H2 2022 H2 2022 H2 2023 Complete Complete HI 2023 lumiraDx™ Note: Regulatorytimelines refer to submission dates and launch dates and will be subject to review by corresponding regulatory authorities. Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide Expected FDA 510K H1 2023 H1 2023 HT 2023 H1 2023 H2 2022 HT 2023 H1 2023 HI JUZI H1 2023 H1 2023 H2 2023 H2 2022 TBC TBC H2 2023 WHO PQ H2 2023 H2 2022 H2 2023 H2 2023 H2 2023 H2 2023 H2 2022 Metabolic/Electrochemical 13

View entire presentation